Black Diamond Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Black Diamond Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Black Diamond Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Black Diamond Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Black Diamond Therapeutics Inc (Black Diamond) is a clinical-stage pharmaceutical company focused on developing therapies for oncogenic mutations in cancer patients. The company's main activities involve the establishment of MasterKey therapies designed to target families of oncogenic mutations, aiming to address genetically defined patient populations and overcome treatment resistance. Black Diamond's major clinical-stage programs include Silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, and BDTX-4933, a brain-penetrant, RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors. It is also focusing on the development of BDTX-4876 for the treatment of achondroplasia or solid tumors. The company has its operations in Massachusetts and New York, the US. Black Diamond is headquartered in Cambridge, Massachusetts, the US
Headquarters
United States of America
Address
245 First Street, 18th Floor, Cambridge, Massachusetts, 02142
Website
www.blackdiamondtherapeutics.com
Telephone
1 617 40184444
No of Employees
21
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BDTX (NASD)
Revenue (2024)
$70.0M
EPS
XYZ
Net Income (2024)
XYZ
132.1%
(2024 vs 2023)
Market Cap*
$120.7M
Net Profit Margin (2024)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Black Diamond Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Silevertinib |
| BDTX-1535: Glioblastoma (GBM) and Non-Small Cell Lung Cancer | |
| BDTX-4933: Central Nervous System Tumors | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In March, the company and Servier entered into a licensing agreement for BDTX-4933, a targeted therapy for RAF/RAS-mutant solid tumors. |
| 2023 | Others | In September, the company announced the first patients dosed in mutation matched expansion cohorts of non-small cell lung cancer in the ongoing Phase 1 clinical study evaluating BDTX-1535. |
| 2022 | Regulatory Approval | In January, the company announced U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application for its MasterKey inhibitor BDTX-1535. |
Competitor Comparison
| Key Parameters | Black Diamond Therapeutics Inc | Merck & Co Inc | AstraZeneca Plc | Bayer AG | Boehringer Ingelheim International GmbH |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Germany | Germany |
| City | Cambridge | Rahway | Cambridge | Leverkusen | Ingelheim am Rhein |
| State/Province | Massachusetts | New Jersey | Cambridgeshire | Nordrhein-Westfalen | Rheinland-Pfalz |
| No. of Employees | 21 | 75,000 | 96,100 | 87,757 | 54,300 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark A Velleca, M.D., Ph.D. | Chief Executive Officer; President; Chairman | Executive Board | 2023 | 62 |
| Brent Hatzis Schoch | Chief Operating Officer; General Counsel | Senior Management | 2019 | 61 |
| Sergey Yurasov, MD, PhD | Chief Medical Officer | Senior Management | 2022 | 57 |
| Elizabeth Buck, PhD | Chief Scientific Officer; Co-Founder | Senior Management | 2021 | 51 |
| Melanie Morrison | Chief Development Officer | Senior Management | 2023 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer